Insider buying last 90 days
No open-market insider purchases were filed for SNY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every SNY insider filing, plotted on the chart in Gekko.Open SNY in Gekko
Gekko Brief
AI summaryNov 4 closeSanofi's week centers on its Q3 2026 results and pipeline moves. The company reported third-quarter sales growth of 14.3% at constant exchange rates, supported by continued demand for Dupixent, recently launched medicines and growth in rare diseases. Separately, Sanofi discontinued the Phase 1 trial for SAR448272, an oral STAT6 degrader developed with Nurix Therapeutics, ending that autoimmune disease program. Sanofi's CEO has also signaled plans to pursue late-phase and commercial deals to support a turnaround ahead of Dupixent's patent expiration, while noting that Dupixent may be the primary beneficiary of a rival's marketing push for a competing drug.
Shares closed at $47.47, up 4.7%, sitting above both the 50-day average of $42.22 and the 200-day average of $44.32. The GekkoIndex reads 37.4, placing the stock in the Distribution zone. Price remains 33.7% below Gekko Fair Value of $71.63.
Looking ahead, the next earnings report is scheduled for 4 February 2027, 91 days out, placing it beyond a typical 20-trading-day window. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality data show the next 20 trading days have averaged -2.3% over 5 years, rising in 3 of them. Consensus among 2 firms shows 1 buy and 1 hold, with a consensus target of $53.48.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Sanofi price vs fair value
Close $47.47200-day averageGekko Fair Value $71.63
Sanofi quick facts
- Market cap
- $113.7B
- P/E ratio
- 22.7
- Forward P/E
- 9.4
- EPS, TTM
- $2.01
- Revenue, TTM
- $50.98B
- Profit margin
- 8.2%
- Dividend yield
- 0.00%
- Beta
- 0.27
- Volume
- 5.48M avg 4.46M
- 1-year return
- −5.2%
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4.1%
- 50-day average
- $42.22
- 200-day average
- $44.32
- Next earnings
- Feb 4 before open
- Shares outstanding
- 2.40B
Sanofi swing-trade checklist
Sanofi scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $47.47 sits between the 50-day ($42.22) and 200-day ($44.32) averages, or the averages disagree.
See the chart - GekkoIndexheadwind
37.4, Distribution
Reading 37.4 is in the Distribution zone.
See the GekkoIndex - Fair valuesupportive
33.7% below
Price is 33.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 91 days
Next report Feb 4, 2027, 91 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−2.3% on average
From this point in the calendar, the next 20 trading days averaged −2.3% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Sanofi stock chart and price history
Sanofi closed at $47.47 on Nov 4, 2026, −5.2% over the past year, inside a 52-week range of $39.07 to $52.68.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +20.0%
- 3 months
- +10.7%
- 6 months
- +8.5%
- 1 year
- −5.2%
The full SNY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SNY in Gekko
Follow Sanofi through every session
Put SNY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SNY in GekkoFree for 7 days. No credit card required.
About Sanofi
Sanofi researches, develops, manufactures and sells a broad range of health-related products across the United States, Europe and other international markets. It is known for its work spanning prescription medicines, vaccines and everyday consumer health items, reaching patients and consumers through therapies for serious conditions as well as common over-the-counter remedies.
The company is structured around three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. Its pharmaceutical work includes monoclonal antibodies and treatments for multiple sclerosis, neurological and immune-related disorders, cancer, rare diseases and rare blood conditions, alongside diabetes and cardiovascular medicines and long-established prescription drugs. The vaccines side covers childhood shots against illnesses such as polio, pertussis and Hib, plus flu, meningitis, adult booster and travel-related immunizations. Consumer Healthcare supplies over-the-counter items for allergies, colds, pain, digestion and wellness, as well as skin and personal care products. Sanofi also works with outside partners, including GlaxoSmithKline, Stanford University School of Medicine, and Prellis Biologics, on various research efforts.
Sanofi was founded in 1973 and is headquartered in Paris, France, having previously operated under the name Sanofi-Aventis before adopting its current name in 2011. Its shares trade under the ticker SNY.
- Sector
- Health technology
- Website
- sanofi.com
Sanofi GekkoIndex: the smart money zone
Sanofi’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 37.4, in the Distribution zone, down 15.8 points over five sessions.
37.4Distribution
Down 15.8 points over five sessions, from the Neutral zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 34 | +0.6% | +1.6% | ||
| Accumulation | 261 | +0.3% | +0.5% | ||
| Neutral | 334 | −0.4% | −0.9% | ||
| Distribution (current zone) | 21 | 0.0% | −2.1% | ||
| Selling | 0 | Not available | |||
Average SNY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the SNY price, zone by zone.Track SNY in Gekko
Is Sanofi stock overvalued? Gekko Fair Value
Sanofi trades 33.7% below Gekko Fair Value of $71.63, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Sanofi shares are worth, recalculated every trading day.
$71.63
Gekko Fair Value, Nov 4, 2026
33.7% Undervalued
At the end of Aug 2026 the price was 46.4% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open SNY in Gekko
Sanofi insider and Congress trading
No open-market insider purchases were filed for Sanofi, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in SNY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for SNY, plotted on the chart in Gekko.Open SNY in Gekko
Hedge funds and billionaires quarter ended Mar 31
0of the funds Gekko tracks hold SNY.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Sanofi earnings: next date and track record
Sanofi reports on Feb 4, 2027, before the open (91 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Feb 4, 2027
Expected before the open, 91 days away
- EPS estimate
- $1.02
- Revenue estimate
- $14.41B
6 of 8reports beat the EPS estimate
±3.2%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 30, 2026 AI summary
- What they said
- Sanofi reported strong Q2 2026 results with double-digit sales growth driven by Dupixent (+37%) surpassing EUR 5 billion quarterly sales for the first time, and launch portfolio growing over 60%. Key contributors included ALTUVIIIO, Ayvakit, and Sarclisa. Rare disease sales reached nearly EUR 1.9 billion (+24%). Management upgraded full-year 2026 guidance based on H1 strength, and raised Dupixent's 2030 sales ambition to approximately EUR 25 billion.
- Guidance
- Full-year 2026 guidance upgraded following strong H1 performance, with management planning continued sales and EPS growth in H2, though at a lower growth rate. Dupixent 2030 target raised to ~EUR 25 billion reflecting sustained momentum.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $1.21 est $1.10 | $14.06B est $15.34B | −3.9% |
| Apr 23, 2026 | $1.10 est $1.03 | $12.94B est $12.68B | −0.3% |
| Jan 29, 2026 | $0.89 est $0.84 | $14.34B est $11.71B | +2.8% |
| Oct 24, 2025 | $1.70 est $1.60 | $15.43B est $11.11B | +3.8% |
| Jul 31, 2025 | $0.91 est $1.00 | $12.64B est $12.36B | −5.1% |
| Apr 24, 2025 | $0.94 est $0.90 | $11.63B est $10.00B | −1.3% |
| Jan 30, 2025 | $0.68 est $0.74 | $7.90B est $9.51B | +4.2% |
| Oct 25, 2024 | $1.54 est $1.38 | $15.53B est $13.94B | +4.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Sanofi stock forecast and analyst price targets
Analysts’ average 12-month price target for Sanofi is $53.48, +12.7% from the last close, from 2 firms rating the stock in the last 90 days.
$53.48consensus 12-month target, +12.7% from the last close
Now $47.47Avg $53.48
Low $57High $62
Each firm’s latest rating in the last 90 days: 2 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 31 | TD Cowen | $57 | +20.1% |
| Aug 24 | Berenberg Bank | $62 | +30.6% |
−2.1%average 20-day move after past Distribution readings
−2.3%average move over the next 20 trading days in the last 5 years
±2.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Sanofi seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Sanofi averaged −2.3% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.2% | 2 of 5 |
| Next 10 trading days | −0.7% | 3 of 5 |
| Next 15 trading days | −0.9% | 3 of 5 |
| Next 20 trading days | −2.3% | 3 of 5 |
| Next 30 trading days | −0.3% | 2 of 5 |
For scale, SNY’s typical 20-trading-day move in either direction is about 4.1%.
Sanofi market cap and key statistics
Sanofi’s market cap is $113.7B, with a P/E ratio of 22.7 and revenue of $50.98B over the last twelve months.
Valuation
- Market cap
- $113.7B
- P/E ratio
- 22.7
- Forward P/E
- 9.4
- EPS, TTM
- $2.01
- Gekko Fair Value
- $71.63
Trading
- Volume
- 5.48M
- Avg volume, 20 days
- 4.46M
- 52-week high
- $52.68
- 52-week low
- $39.07
- Shares outstanding
- 2.40B
Financials
- Revenue, TTM
- $50.98B
- Profit margin
- 8.2%
- Return on equity
- 5.7%
- Quarterly earnings growth, YoY
- +9.4%
Risk and income
- Beta
- 0.27
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4.1%
- Dividend yield
- 0.00%
Sanofi stock news this week
Coverage of Sanofi this week reads positive: 6 positive, 2 neutral and 1 negative headlines.
- Sanofi Discontinues Nurix Therapeutics STAT6 Degrader ProgramTipRanks, Nov 3
- Nurix says Sanofi discontinues autoimmune disease drug programReuters, Nov 3
- Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272GlobeNewsWire, Nov 3
- Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone RevenuesZacks Investment Research, Nov 3
- Sanofi tips Dupixent to reap most rewards from Eli Lilly’s Ebglyss ad pushFierce Pharma, Nov 2
- Sanofi CEO Sets Sights on Deals to Drive TurnaroundWSJ, Oct 31
Sanofi stock FAQ
What is Sanofi’s market cap?
Sanofi’s market cap is $113.7B at the Nov 4, 2026 close of $47.47, with 2.40B shares outstanding. The shares trade on a P/E ratio of 22.7.
What is the Sanofi stock forecast?
The consensus analyst 12-month price target for Sanofi is $53.48, +12.7% from the last close. Of the 2 firms that rated the stock in the last 90 days, 1 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Sanofi stock overvalued or undervalued?
On Gekko’s estimate Sanofi is undervalued: the Nov 4, 2026 close of $47.47 is 33.7% below Gekko Fair Value of $71.63. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Sanofi report earnings next?
Sanofi is expected to report on Feb 4, 2027, before the market opens (91 days away). Analysts expect earnings of $1.02 per share on revenue of $14.41B. Sanofi beat the earnings estimate in 6 of its last 8 reports, moving 3.2% on average across the report.
What is Sanofi’s 52-week high and low?
Sanofi’s 52-week high is $52.68 and its 52-week low is $39.07; it closed at $47.47 on Nov 4, 2026, −5.2% over the past year. Over the last five years the shares peaked at $60.12 on Mar 10, 2025.
Is Sanofi stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and earnings risk), 2 as mixed (trend and seasonality) and 1 as a headwind (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Sanofi the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.